

Curriculum Vitae  
**Aamir Ahmad, PhD**

**Senior Research Scientist**

Interim Translational Research Institute  
Hamad Medical Corporation  
Building 320, Hamad Medical City  
Doha, Qatar

Tel: +974-44390984 (Office)  
Tel: +974-55256139 (Cell)  
E-mail: aahmad9@hamad.qa

---

**Positions and Trainings**

Nov, 2020 – Present	<b>Group Leader &amp; Senior Research Scientist</b> , Interim Translational Research Institute, Hamad Medical Corporation, Doha, Qatar
Jul, 2019 – Nov, 2020	<b>Associate Scientist</b> , University of Alabama at Birmingham, Birmingham, AL, USA
Feb, 2016 – Jul, 2019	<b>Assistant Professor</b> , Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA
Aug, 2011 – Jan, 2016	<b>Research Scientist</b> , Pathology/Medicine, Wayne State University & Karmanos Cancer Institute, Detroit, MI, USA
Dec, 2006 – Aug, 2011	<b>Research Associate</b> , Pathology/Medicine, Wayne State University & Karmanos Cancer Institute, Detroit, MI, USA
Apr, 2004 – Dec, 2006	<b>Visiting Scholar</b> , National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda MD, USA
Mar, 2002 – Mar, 2004	<b>Research Associate</b> , Nephrology/Medicine, University of Louisville, Louisville KY, USA

**Education**

**Ph.D.** AMU, Aligarh, India. Feb 2002

**M.S.** in Biochemistry, 1997, 1st Division, AMU, Aligarh, India

**B. S.** (Honors) in Biochemistry, 1995, 1st position, AMU, Aligarh, India

Department and University Gold Medalist

**Awards and Recognitions**

- Ranked among the top 2% scientists for career-long citation impact as well as citation impact during the calendar year, in the 2022 data-update list based on data from Mendeley and Scopus
- Keynote address on 'Precision Medicine and Pharmacogenetics' at ZIPC2002, Al Zaytoonah University, Amman, Jordan, October 18, 2022
- Ranked among the top 2% scientists for career-long citation impact, in the 2021 list based on data from Mendeley and Scopus
- Ranked among the top 2% scientists for career-long citation as well as citation impact during the calendar year, in the 2020 list published by Stanford University
- Ranked among the top 10 editors worldwide in Publons' global editor database, as determined by the number of manuscripts handled for different journals during the 2018-2019 award year
- Placed within top 1% of reviewers in *Molecular Biology & Genetics*, *Clinical Medicine* and *Cross Field* for the Publons 2018-2019 award year
- Ranked 3<sup>rd</sup> on Publons' global editor database for the 2017-2018 award year
- Placed within top 1% of reviewers in *Molecular Biology & Genetics* and *Clinical Medicine*, for the Publons 2017-2018 award year

- Outstanding Researcher, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA (Year 2005)
- University Gold medal for highest marks in B.S. (Hons.) Biochemistry
- University Gold medal for securing first place in all the faculties combined (Year 1995)
- University Post Graduate Merit Scholarship, 1995-96 and 1996-97
- CSIR Senior Research Fellow (April 2000 - Feb 2002)
- CSIR Junior Research Fellow (April 1998 - March 2000)
- UGC Junior Research Fellow (November 1997 - March 1998)
- All India 16<sup>th</sup> Rank in GATE-97, conducted by IIT, Madras (98.65 percentile score)
- Qualified CSIR-UGC NET for JRF ship and lectureship twice (12/1996 and 06/1997)

## Other Honors

- Editor-in-Chief, Elsevier/KeAi Journal “Non-coding RNA Research”
- Editor-in-Chief, Book series “Cancer Metastasis” (Publishers - Elsevier Inc.)
- Scientific Committee Member, 2nd International Electronic Conference on Cancers (IECC 2022); Tumor Microenvironment Heterogeneity in Cancer Progression: Challenge or Opportunity, 14–16 February 2022.
- Member, Organizing Committee, ‘5<sup>th</sup> NanoBio Summit’, Atmore, Alabama, USA Nov 9-10, 2017
- Member, Organizing Committee, ‘International Conference on Cancer Immunology and Immunotherapy’, Melbourne, Australia July 28-30, 2016
- Invited by ISRN Oncology to write a spotlight article on Breast Cancer Recurrence

## Membership of Scientific Associations

- *Member, Cancer Epigenetics Society, Vienna, Austria*
- *Member, Society of Hematologic Oncology, USA*
- *Associate Member, AACR (American Association for Cancer Research, Philadelphia, USA)*
- *Member, Association of UICC Fellows (International Union Against Cancer, Geneva, Switzerland)*

## Expert Reviewer of Research Grant Proposals

- Fund for Scientific Research (FNRS), Brussels, Belgium – 2022
- Fund for Scientific Research (FNRS), Brussels, Belgium – 2021
- National Science Centre (Narodowe Centrum Nauki – NCN), Poland - 2021
- Arabian Gulf University, Bahrain - 2021
- Fund for Scientific Research (FNRS), Brussels, Belgium – 2020
- National Science Centre (Narodowe Centrum Nauki – NCN), Poland - 2020
- Fund for Scientific Research (FNRS), Brussels, Belgium – 2019
- National Science Centre (Narodowe Centrum Nauki – NCN), Poland - 2019
- Italian Ministry for Education, University and Research – 2018
- Fund for Scientific Research (FNRS), Brussels, Belgium – 2018
- The Thailand Research Fund, Thailand - 2018
- Fund for Scientific Research (FNRS), Brussels, Belgium – 2017
- National Science Center, Poland - 2017
- Sultan Qaboos University, Oman - 2017
- Swiss National Science Foundation, Bern, Switzerland – 2016
- Fund for Scientific Research (FNRS), Brussels, Belgium - 2016

- South African Medical Research Council - 2016
- Swiss National Science Foundation, Bern, Switzerland - 2015
- Research Council of Oman, Oman –2015
- Arabian Gulf University, Bahrain - 2015
- Research Council of Oman, Oman –2015
- Sultan Qaboos University, Oman - 2014
- Croatian Science Foundation, Zagreb, Croatia - 2013

## Teaching Experience

1. Cancer Chemotherapy Class for Graduate Students  
Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA  
Winter 2017
2. General Education Faculty (*BioChemistry*)  
Al Michigan, Novi and Troy, MI, USA  
April, 2009 – Dec 2015
3. Adjunct Faculty (*Science-Chemistry*) at *Henry Ford Community College, Dearborn, MI, USA*  
Aug 2010 – Jan 2016
4. Guest Lecture Faculty (Cancer Biology)  
Wayne State University, Detroit, MI, USA  
Winter 2008, Winter 2009
5. Teaching Assistant (Molecular Cell Biology, Molecular Genetics and Immunology)  
AMU, Aligarh, India  
1999-2001

## Research Funding (Current)

1. Epigenetic underpinnings of epithelial mesenchymal transition in cutaneous squamous cell carcinoma cells (MRC-01-21-118). PI: Aamir Ahmad
2. Exploring the role of miR-200 family in epithelial mesenchymal transition of cutaneous squamous cell carcinoma cells (MRC-01-21-330). PI: Aamir Ahmad
3. MicroRNAs mediated inflammation in Cutaneous T-cell lymphoma (MRC-01-21-499). PI: Aamir Ahmad
4. Identifying an epigenetic signature for atopic dermatitis involving inflammation regulating microRNAs (MRC-01-22-086). PI: Aamir Ahmad

## Research Publications (h-index = 68 / Total citations = 15817; Source: Google Scholar)

1. Patil et al. (2022). The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: emphasis on therapeutic opportunities. *Seminars in Cell and Developmental Biology* [In Press].
2. Aamir Ahmad (2022). Exosomes in Cancer Diagnosis and Therapy. *International Journal of Molecular Sciences* [In Press]. \*Editorial
3. Khan and Ahmad (2022). LncRNA SNHG6 sponges miR-101 and induces tamoxifen resistance in breast cancer cells through induction of EMT. *Frontiers in Oncology* [In Press].
4. Dalhat et al. (2022). NAT10, an RNA cytidine transferase regulates fatty acid metabolism in cancer cells. *Clinical and Translational Medicine* [In Press].
5. Khan et al. (2022). Targeting deregulated oxidative stress in skin inflammatory diseases: An update on clinical importance. *Biomedicine & Pharmacotherapy* [In Press].

6. Ahmad (2022). Guest Edited Collection: Epigenetics within the tumor microenvironment. *Scientific Reports* [In Press].
7. Farhan et al. (2022). Pomegranate juice anthocyanidins induce cell death in human cancer cells by mobilizing intracellular copper ions and producing reactive oxygen species. *Frontiers in Oncology* [In Press].
8. Sher et al. (2022). Dysregulated FOXM1 signaling in the regulation of cancer stem cells. *Seminars in Cancer Biology* [In Press].
9. Shaikh et al. (2022). 1,3-diketo curcumin scaffolds: a gateway to profuse bioactive heterocycles. *Annals of Phytomedicine*, **11(1)**, 175-188. DOI: 10.54085/ap.2022.11.1.17
10. Awal et al. (2022). Structural guided identification of small molecule inhibitor of UHRF1 methyltransferase activity. *Frontiers in Genetics* [In Press].
11. Ullah et al. (2022). Functional profiling of *Achillea fragrantissima* (a perennial edible herb) against human cancer cells and potential nutraceutical impact in neutralizing cell proliferation by interfering with VEGF and NF- $\kappa$ B signaling pathways. *Italian Journal of Food Science*, **34(3)**, 35-47.
12. Awal et al. (2022). Structural Guided Identification of small molecule inhibitor of UHRF1 methyltransferase activity. *Frontiers in Oncology* [In Press].
13. Almaghrbi et al. (2022). Analysis of signaling cascades from myeloma cells treated with pristimerin. *Advances in Protein Chemistry and Structural Biology* [In Press].
14. Kuttikrishnan et al. (2022). Bioinformatics analysis reveals FOXM1/BUB1B signaling pathway as a key target of Neosetophomone B in human leukemic cells: A gene network-based microarray analysis. *Frontiers in Oncology* [In Press].
15. Khan et al. (2022). Exosomes-mediated response to cancer therapy: modulation of epigenetic machinery. *International Journal of Molecular Sciences*, **23(11)**, 6222. DOI: 10.3390/ijms23116222
16. Alsayed et al. (2022). Epigenetic Regulation of CXCR4 Signaling in Cancer Pathogenesis and Progression. *Seminars in Cancer Biology* [In Press].
17. Gareev et al. (2022). The role of mitochondria-targeting miRNAs in intracerebral hemorrhage. *Current Neuropharmacology* [In Press].
18. Meshcheryakova et al. (2022). The effect of whole blood and bone marrow with the addition of pyrimidine-2,4(1H,3H)-dione thietanyl derivatives on free radical oxidation. *Current Medicinal Chemistry* [In Press].
19. Tambat et al. (2022). Pyrazine Derivatives – Versatile Scaffold. *Russian Journal of Bioorganic Chemistry* [In Press].
20. Ahmad A (2022). Tumor microenvironment and immune surveillance. *Microenvironment & Microecology Research*, **4(1)**: 6. DOI: 10.53388/MMR2022006
21. Sharma et al. (2022). Cross-talk between the microbiome and chronic inflammation in esophageal cancer; potential driver of oncogenesis. *Cancer and Metastasis Reviews* [In Press].
22. Nur et al. (2022). Untargeted metabolomics showed accumulation of one carbon metabolites to facilitate DNA methylation during extra cellular matrix detachment of cancer cell. *Metabolites* [In Press].
23. Yanchao et al. (2022). Bioinformatics analysis of potential therapeutic targets for COVID-19 infection in patients with carotid atherosclerosis. *Journal of Infection and Public Health* [In Press].
24. Farhan et al. (2022). Structure of green tea catechins and the availability of intracellular copper influence their ability to cause selective oxidative DNA damage in malignant cells. *Biomedicines* [In Press].
25. Alkhatabi et al. (2022). Venetoclax Resistant Leukemic Cells Activate PI3K/AKT Pathway for Metabolic Reprogramming and Redox Adaptation for Survival. *Antioxidants* [In Press].

26. Ullah et al. (2022). Diet-derived small molecules (nutraceuticals) inhibit cellular proliferation by interfering with key oncogenic pathways: An overview of experimental evidence in cancer chemoprevention. *Biologia Futura* [In Press]. DOI: 10.1007/s42977-022-00110-x
27. Kuttikrishnan et al. (2022). Natural Resorcylic Acid Lactones: A Chemical Biology Approach for Anticancer Activity. *Drug Discovery Today*, **27(2)**:547-557. DOI: 10.1016/j.drudis.2021.10.001
28. Ahmad A (2022). Epigenetic regulation of immunosuppressive tumor-associated macrophages through dysregulated microRNAs. *Seminars in Cell and Development Biology*, **124**: 26-33. DOI: 10.1016/j.semcbd.2021.09.001
29. Ahmad A (2021). Special Issue: Epigenetic Regulation of Cancer Progression: Promises and Progress. *Seminars in Cancer Biology*, S1044-579X(21)00298-4. DOI: 10.1016/j.semcancer.2021.12.005 **\*Editorial**
30. Ahmad A et al. (2021). LncRNAs in cancer metastasis and therapy resistance. *Frontiers in Oncology*, **11**:813274. DOI: 10.3389/fonc.2021.813274 **\*Editorial**
31. Patil et al. (2021). Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways. *Seminars in Cancer Biology*, S1044-579X(21)00296-0. DOI: 10.1016/j.semcancer.2021.12.003
32. Gareev et al. (2021). The role of miRNAs in therapeutic resistance of malignant primary brain tumors. *Frontiers in Cell and Development Biology*, **9**:740303. DOI: 10.3389/fcell.2021.740303
33. Ahmad et al. (2021). Long non-coding RNAs Regulated NF- $\kappa$ B Signaling in Cancer Metastasis: Micromanaging by Not So Small Non-coding RNAs. *Seminars in Cancer Biology*, S1044-579X(21)00210-8. DOI: 10.1016/j.semcancer.2021.07.015
34. Gareev et al. (2021). Long Non-coding RNAs in Oncurology. *Non-coding RNA Research*, **6(3)**:139-145. DOI: 10.1016/j.ncrna.2021.08.001
35. Ahmad et al. (2021). Epigenetic underpinnings of inflammation: connecting the dots between pulmonary diseases, lung cancer and COVID-19. *Seminars in Cancer Biology*, S1044-579X(21)00008-0. DOI: 10.1016/j.semcancer.2021.01.003
36. Patil et al. (2021). The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance. *Cancer and Metastasis Reviews*, **40(3)**:691-720. DOI: 10.1007/s10555-021-09979-x.
37. Kuttikrishnan et al. (2021). Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor Acute Lymphoblastic Leukemia cells. *Leukemia and Lymphoma*, **62(13)**:3170-3180. DOI: 10.1080/10428194.2021.1957873
38. Sun et al. (2021). Exosomal miR-2276-5p in plasma is a potential diagnostic and prognostic biomarker in glioma. *Frontiers in Cell and Development Biology*, **9**:671202. DOI: 10.3389/fcell.2021.671202
39. Beylerli et al. (2021). Differential Non-coding RNAs Expression Profiles of Invasive and Non-Invasive Pituitary Adenomas. *Non-coding RNA Research* **6(3)**, 115-122. DOI: 10.1016/j.ncrna.2021.06.004
40. Juncos et al. (2021). Sex differences in cardiopulmonary effects of acute bromine exposure. *Toxicology Research*, **10(5)**:1064-1073. DOI: 10.1093/toxres/tfab079
41. Beilerli et al. (2021). Circular RNAs as Biomarkers and Therapeutic Targets in Cancer. *Seminars in Cancer Biology*, S1044-579X(21)00004-3. DOI: 10.1016/j.semcancer.2020.12.026
42. Rizvi et al. (2021) Transcriptional control of the oxidative stress response and implications of using plant derived molecules for therapeutic interventions in cancer. *Current Medicinal Chemistry*, **28(41)**:8480-8495. DOI: 10.2174/0929867328666210218110550
43. Laskar et al. (2021). Yb/chitosan catalyzed synthesis of highly substituted piperidine derivatives for potential nuclease activity and DNA binding study. *Current Pharmaceutical Design*, **27(19)**:2252-2263. DOI: 10.2174/1381612826666201210114343

44. Dandawate *et al.* (2021). Anticancer active heterocyclic chalcones: Recent developments. *Anti-Cancer Agents in Medicinal Chemistry*, **21(5)**:558-566. DOI: 10.2174/1871520620666200705215722.
45. Aamir Ahmad (2020). CAR-T Cell Therapy. *International Journal of Molecular Sciences* **21(12)**, 4303. DOI: 10.3390/ijms21124303. **\*Editorial**
46. Khan *et al.* (2020). Exosomes: emerging diagnostic and therapeutic targets in cutaneous diseases. *International Journal of Molecular Sciences* **21(23)**, 9264. DOI: 10.3390/ijms21239264.
47. Juncos *et al.* (2020). Circulating and tissue biomarkers as predictors of bromine gas inhalation. *Annals of the New York Academy of Sciences* **1480 (1)**, 104-115. DOI: 10.1111/nyas.14422.
48. Rana *et al.* (2020). MicroRNA-mediated inflammation and coagulation effects in rats exposed to an inhaled analog of sulfur mustard. *Annals of the New York Academy of Sciences* **1479 (1)**, 148-158. DOI: 10.1111/nyas.14416.
49. Farooqi *et al.* (2020). EGCG Mediated Targeting of Deregulated Signaling Pathways and Non-coding RNAs in Different Cancers: Focus on JAK/STAT, Wnt/ $\beta$ -Catenin, TGF/SMAD, NOTCH, SHH/GLI and TRAIL mediated Signaling Pathways. *Cancers* **12(4)**, 951. DOI: 10.3390/cancers12040951.
50. Manzoor *et al.* (2020). Cutaneous lewisite exposure causes acute lung injury. *Annals of the New York Academy of Sciences* **1479 (1)**, 210-222. DOI: 10.1111/nyas.14346.
51. Ahmad *et al.* (2020). CAR-T Cell Therapies: An overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas. *International Journal of Molecular Sciences* **21(11)**, 3906. DOI: 10.3390/ijms21113906.
52. Khan *et al.* (2020). Sanguinarine induces apoptosis in papillary thyroid cancer cells via generation of reactive oxygen species. *Molecules* **25(5)**, 1229. DOI: 10.3390/molecules25051229.
53. Aziz *et al.* (2020). Epigenetic basis of cancer drug resistance. *Cancer Drug Resist.* **3**, 200-203. DOI: 10.20517/cdr.2020.06. **\*Editorial**
54. Khan *et al.* (2020). Curcumin-mediated apoptotic cell death in papillary thyroid cancer and cancer stem-like cells through targeting of JAK/STAT3 signaling pathway. *International Journal of Molecular Sciences* **21(2)**, 438. DOI: 10.3390/ijms21020438.
55. Fayyaz *et al.* (2019). MicroRNA Regulation of TRAIL Mediated Signaling in Different Cancers: Control of Micro Steering Wheels during the Journey from Bench-Top to the Bedside. *Seminars in Cancer Biology* pii: S1044-579X(18)30191-3. DOI: 10.1016/j.semcancer.2019.01.007.
56. Aamir Ahmad (2019). Breast Cancer Statistics: Recent Trends. *Adv Exp Med Biol* **1152**, 1-7. DOI: 10.1007/978-3-030-20301-6\_1.
57. Farhan *et al.* (2019). Non-coding RNAs as Mediators of Tamoxifen Resistance in Breast Cancers. *Adv Exp Med Biol* **1152**, 229-241. DOI: 10.1007/978-3-030-20301-6\_11
58. Aamir Ahmad (2019). Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers. *Adv Exp Med Biol* **1152**, 217-228. DOI: 10.1007/978-3-030-20301-6\_10.
59. Aamir Ahmad (2019). Cancer Epigenetics: Clinical Perspectives. *Current Cancer Drug Targets* **19(7)**, 513-514. DOI: 10.2174/156800961907190802112321. **\*Editorial Perspective**
60. Farhan *et al.* (2019). Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs. *International Journal of Molecular Sciences* **20(4)**, 800. DOI: 10.3390/ijms20040800.
61. Ahmad *et al.* (2019). Pentafluorophenyl substitution of natural di(indol-3-yl)methane strongly enhances growth inhibition and apoptosis induction in various cancer cell lines. *Chemistry and Biodiversity* **16(4)**, e1900028. DOI: 10.1002/cbdv.201900028.
62. Farooqi and Ahmad (2019). Gaze through the Clinical Lens: Molecular and Clinical Advancements of Botanicals. *Future Medicinal Chemistry* **11(2)**, 75-77. DOI: 10.4155/fmc-2018-0371

63. Ullah MF *et al.* (2019). Impact of sex differences and gender specificity on behavioral characteristics and pathophysiology of neurodegenerative disorders. *Neuroscience & Biobehavioral Reviews* **102**, 95-105. DOI: 10.1016/j.neubiorev.2019.04.003.
64. Dankhoff K *et al.* (2019). Anticancer properties of a new non-oxido vanadium(IV) complex with a catechol-modified 3,3'-diindolylmethane ligand. *Journal of Inorganic Biochemistry* **194**, 1-6. DOI: 10.1016/j.jinorgbio.2019.02.005.
65. Shahwar *et al.* (2019). Natural products mediated regulation of death receptors and intracellular machinery: Fresh from the pipeline about TRAIL mediated signaling and natural TRAIL-sensitizers. *International Journal of Molecular Sciences* **20(8)** pii: E2010. doi: 10.3390/ijms20082010.
66. Farhan *et al.* (2019). Differential Methylation and Acetylation as the Epigenetic Basis of Resveratrol's Anticancer Activity. *Medicines* **6(1)**, 24. DOI: 10.3390/medicines6010024.
67. Aamir Ahmad (2018). Cancer Epigenetics. *Current Cancer Drug Targets* **18(1)**, 3-4. DOI: 10.2174/156800961801171208144307. **\*Editorial**
68. Tian *et al.* (2018). Prostate Cancer: Updates on Current Strategies for Screening, Diagnosis and Clinical Implications of Treatment Modalities. *Carcinogenesis* **39(3)**, 307-317. DOI: 10.1093/carcin/bgx141.
69. Farooqi *et al.* (2018). Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers. *International Journal of Molecular Sciences* **19(3)**, pii: E652; DOI:10.3390/ijms19030652.
70. Arif *et al.* (2018). Flavonoids-induced redox cycling of copper ions leads to generation of reactive oxygen species: A potential role in cancer chemoprevention. *Int J Biol Macromol.* **106**, 569-578. DOI: 10.1016/j.ijbiomac.2017.08.049.
71. Ahmad A *et al.* (2017) Epigenetic Basis of Cancer Health Disparities: Looking Beyond Genetic Differences. *BBA - Reviews on Cancer* **1868(1)**, 16-28. DOI: 10.1016/j.bbcan.2017.01.001
72. Farooqi *et al.* (2017). MicroRNA-34a: a versatile regulator of myriads of targets in different cancers. *International Journal of Molecular Sciences* **18(10)**, E2089. DOI:10.3390/ijms18102089.
73. Tyagi *et al.* (2017) ETV4 Facilitates Cell Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1. *Molecular Cancer Research* **16(2)**, 187-196. DOI: 10.1158/1541-7786.MCR-17-0219.
74. Srivastava *et al.* (2017) MicroRNAs in gynecological cancers: small molecules with big implications. *Cancer Letters* **407**, 123-138. DOI:10.1016/j.canlet.2017.05.011.
75. Zubair *et al.* (2017) Hydroxytyrosol induces apoptosis, cell cycle arrest and suppresses multiple oncogenic signaling pathways in prostate cancer cells. *Nutrition and Cancer* **69(6)**, 932-942. DOI: 10.1080/01635581.2017.1339818.
76. Deshmukh *et al.* (2017) Emerging evidence for the role of differential tumor microenvironment in breast cancer racial disparity: a closer look at the surroundings. *Carcinogenesis* **38(8)**, 757-765. DOI: 10.1093/carcin/bgx037.
77. Zubair *et al.* (2017) Cancer chemoprevention by phytochemicals: nature's healing touch. *Molecules* **22(3)**, E395. DOI: 10.3390/molecules22030395.
78. Deshmukh *et al.* (2017) Biological basis of cancer health disparities: resources and challenges for research. *Am J Cancer Res.* **7(1)**, 1-12.
79. Srivastava\* *et al.* (2017). Racial health disparities in ovarian cancer: not just black and white. *J Ovarian Res.* **10(1)**:58. DOI: 10.1186/s13048-017-0355-y\***Equal Contributing First Author**
80. Farhan *et al.* (2017) Mobilization of Nuclear Copper by Green Tea Polyphenol Epicatechin-3-Gallate and Subsequent Prooxidant Breakage of Cellular DNA: Implications for Cancer Chemotherapy. *International Journal of Molecular Sciences* **18(1)**, E34; DOI:10.3390/ijms18010034.

81. Mahal *et al.* (2017) Improved anticancer and antiparasitic activity of new lawsone Mannich bases. *Eur J Med Chem* **126** 421-431. DOI:10.1016/j.ejmech.2016.11.043.
82. Aamir Ahmad (2016) Non-coding RNAs: a tale of junk turning into treasure. *Non-coding RNA Research* **1(1)**, 1-2. **\*Editorial Perspective**
83. Aamir Ahmad (2016) Epigenetics in Personalized Management of Lung Cancers. *Advances in Experimental Medicine and Biology*. **890** (Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management), 111-122. DOI: 10.1007/978-3-319-24932-2\_6.
84. Zubair *et al.* (2016) Mobilization of Intracellular Copper by Gossypol and Apogossypolone Leads to Reactive Oxygen Species-Mediated Cell Death: Putative Anticancer Mechanism. *International Journal of Molecular Sciences* **17(5)**, pii: E973. DOI: 10.3390/ijms17060973.
85. Ahmad A *et al.* (2016) Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management: Preface. *Adv Exp Med Biol*. **890**, v-vi.
86. Farhan *et al.* (2016) Cancer Therapy by Catechins Involves Redox Cycling of Copper Ions and Generation of Reactive Oxygen species. *Toxins* **8(2)**, 37. DOI: 10.3390/toxins8020037.
87. Ahmad *et al.* (2016) New ferrocene modified lawsone Mannich bases with anti-proliferative activity against tumor cells. *Journal of Saudi Chemical Society*, **21(1)**, 105-110. DOI:10.1016/j.jscs.2016.03.005.
88. Ullah *et al.* (2016) Simulating hypoxia-induced acidic environment in cancer cells facilitates mobilization and redox-cycling of genomic copper by daidzein leading to pro-oxidant cell death: implications for the sensitization of resistant hypoxic cancer cells to therapeutic challenges. *Biometals* **29(2)**, 299-310. DOI: 10.1007/s10534-016-9916-6.
89. Ahmad *et al.* (2016) The bounty of nature for changing the cancer landscape. *Molecular Nutrition & Food Research* **60(6)**, 1251-1263. DOI: 10.1002/mnfr.201500867.
90. Zubair *et al.* (2016) Glucose metabolism reprogrammed by overexpression of IKK $\epsilon$  promotes pancreatic tumor growth. *Cancer Research* **76(24)** 7254-7264.
91. Muenzner *et al.* (2016) Ferrocene-substituted 3,3'-diindolylmethanes with improved anticancer activity. *Appl. Organometal. Chem.* **30**, 441–445. DOI:10.1002/aoc.3452.
92. Averett *et al.* (2016) Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor–stromal cross-talk. *Carcinogenesis* **37 (11)**: 1052-1061 DOI:10.1093/carcin/bgw096.
93. Azim *et al.* (2016) Deep sequencing and in silico analyses identify MYB-regulated gene networks and signaling pathways in pancreatic cancer. *Scientific Reports* **6**, 28446 DOI: 10.1038/srep28446.
94. Suresh *et al.* (2016) The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. *Advances in Experimental Medicine and Biology* **890**, 57-74. DOI:10.1007/978-3-319-24932-2\_4.
95. **Ahmad *et al.* (2015)** Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. *BMC Cancer* **15(1)**:540. doi:10.1186/s12885-015-1561-x.
96. Mahal *et al.* (2015) Role of JNK and NF- $\kappa$ B in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells. *Cellular Oncology* **38(6)**, 463-478. DOI:10.1007/s13402-015-0243-7.
97. Li *et al.* (2015) ASPP and iASPP: Implication in cancer development and progression. *Cellular and Molecular Biology* **61(6)**, 2-8.
98. Michelhaugh *et al.* (2015) Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1. *Journal of Translational Medicine* **13**:227. DOI:10.1186/s12967-015-0596-8.
99. Ishtikhar *et al.* (2015) Rosin Surfactant QRMAE Can Be Utilized as an Amorphous Aggregate Inducer: A Case Study of Mammalian Serum Albumin. *PLoS One* **10(9)**, e0139027. DOI: 10.1371/journal.pone.0139027.



100. Arif *et al.* (2015) Mobilization of copper ions by flavonoids in human peripheral lymphocytes leads to oxidative DNA breakage: A structure activity study. *International Journal of Molecular Sciences* **16 (11)**, 26754-26769. DOI: 10.3390/ijms161125992.
101. Ahmad *et al.* (2015) miR-20b is up-regulated in brain metastases from primary breast cancers. *Oncotarget* **6(14)**, 12188-95.
102. Ahmad *et al.* (2015) Molecular docking and Inhibition of Matrix Metalloproteinase-2 by Novel Difluorinatedbenzylidene Curcumin Analog. *Am J Transl Res.* **7(2)**, 298-308.
103. Farhan *et al.* (2015) Targeting increased copper levels in diethylnitrosamine induced hepatocellular carcinoma cells in rats by epigallocatechin-3-gallate. *Tumor Biology* **36(11)**, 8861-8867. DOI: 10.1007/s13277-015-3649-y.
104. Ahmad *et al.* (2015) Molecular Targets of Naturopathy in Cancer Research: Bridge to Modern Medicine. *Nutrients*, **7(1)**, 321-334. DOI:10.3390/nu7010321.
105. Dandawate *et al.* (2014) Anticancer phytochemical analogs 37: Synthesis, characterization, molecular docking and cytotoxicity of novel plumbagin hydrazones against breast cancer cells. *Bioorganic & Medicinal Chemistry Letters* **24(13)**, 2900-4. DOI: 10.1016/j.bmcl.2014.04.100.
106. Ahmad *et al.* (2014) Epigenetic regulation of miRNA-Cancer Stem Cells nexus by Nutraceuticals. *Molecular Nutrition & Food Research*, **58(1)**, 79-86. DOI:10.1002/mnfr.201300528.
107. Ullah *et al.* (2014) Cancer chemopreventive pharmacology of phytochemicals derived from plants of dietary and non-dietary origin: Implication for alternative and complementary approaches. *Phytochemistry Reviews* **13(4)**, 811-833. DOI:10.1007/s11101-014-9341-9.
108. Ahmad *et al.* (2014) Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. *Am J Transl Res.* **6(4)**,384-90.
109. Khan *et al.* (2014) Plant Polyphenol induced cell death in human cancer cells involves mobilization of intracellular copper ions and reactive oxygen species generation: A mechanism for cancer chemopreventive action. *Molecular Nutrition & Food Research*, **58(3)**, 437-446. DOI:10.1002/mnfr.201300417.
110. Ullah *et al.* (2014) Pharmacological Intervention through Dietary Nutraceuticals in Gastrointestinal Neoplasia. *Critical Reviews in Food Science and Nutrition* **56(9)**, 1501-1518. DOI:10.1080/10408398.2013.772091.
111. Ginnebaugh *et al.* (2014) The therapeutic potential of targeting the epithelial-mesenchymal transition (EMT) in cancer. *Expert Opinion on Therapeutic Targets* **18(7)**, 731-745. doi: 10.1517/14728222.2014.909807.
112. Ali *et al.* (2014) Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. *Cancer Letters* **351(1)**, 134-42. DOI:10.1016/j.canlet.2014.05.013.
113. Tang *et al.* (2014) MicroRNAs in Breast Cancer Therapy. *Current Pharmaceutical Design* **20(33)**, 5268-5274. DOI: 10.2174/1381612820666140128205239.
114. Bao *et al.* (2014) Differentially Expressed miRNAs in Cancer-Stem-Like Cells: Markers for Tumor Cell Aggressiveness of Pancreatic Cancer. *Stem Cells and Development* **23(16)**, 1947-1958. DOI:10.1089/scd.2013.0551.
115. Bao *et al.* (2014) Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness. *Current Stem Cell Research & Therapy* **9(1)**, 22-35
116. Li *et al.* (2014) Recent progress on nutraceutical research in prostate cancer. *Cancer and Metastasis Reviews* **33**, 629-640. DOI 10.1007/s10555-013-9478-9.
117. Bao *et al.* (2014) Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. *J Biol Chem*, **289(21)**:14520-14533. DOI: 10.1074/jbc.M113.532887
118. Aamir Ahmad (2013) Pathways to Breast Cancer Recurrence. *ISRN Oncology*, **2013**, 290568. DOI: 10.1155/2013/290568.

**Invited Spotlight article**

119. Zubair *et al.* (2013) Redox cycling of endogenous copper by thymoquinone leads to ROS-mediated DNA breakage and consequent cell death: putative anticancer mechanism of antioxidants. *Cell Death and Disease*, **4**:e660. DOI:10.1038/cddis.2013.172.
120. Li *et al.* (2013) Targeting MicroRNAs for Personalized Cancer Therapy. *Medical Principles and Practice*, **22(5)**, 415-417. DOI:10.1159/000353562.
121. Bao *et al.* (2013) Overview of Cancer Stem Cells (CSCs) and Mechanisms of Their Regulation: Implications for Cancer Therapy. *Current Protocols in Pharmacology*. Jun; Chapter 14: Unit14.25. DOI:10.1002/0471141755.ph1425s61.
122. Li *et al.* (2013) Antioxidant function of isoflavone and 3,3'-diindolylmethane: Are they important for cancer prevention and therapy? *Antioxidants & Redox Signaling*, **19(2)**, 139-150. DOI:10.1089/ars.2013.5233.
123. Afrasiabi *et al.* (2013) Metal-based anticancer agents: targeting androgen-dependent and androgen-independent prostate and COX-positive pancreatic cancer cells by phenanthrenequinone semicarbazone and its metal complexes. *Transition Metal Chemistry*, **38(6)**, 665-673. DOI: 10.1007/s11243-013-9735-3.
124. Ali *et al.* (2013) The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis. *Journal of Cellular Physiology*, **228(1)**, 36-42. DOI:10.1002/jcp.24127.
125. Tang *et al.* (2013) Erlotinib resistance in lung cancer: current progress and future perspectives. *Frontiers in Pharmacology*, **4**:15. DOI: 10.3389/fphar.2013.00015.
126. Ahmad *et al.* (2013) Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. *Journal of Hematology & Oncology*, **6(1)**, 77. DOI:10.1186/1756-8722-6-77.
127. Vyas *et al.* (2013) Perspectives on new synthetic curcumin analogs and their potential anticancer properties. *Current Pharmaceutical Design*, **19(11)**, 2047-2069.
128. Ahmad *et al.* (2013) 3, 3'-diindolylmethane enhances the effectiveness of Herceptin against HER2/neu-expressing breast cancer cells. *PLoS ONE*, **8(1)**, e54657. DOI:10.1371/journal.pone.0054657.
129. Ahmad *et al.* (2013) Perspectives on the role of Isoflavones in Prostate Cancer. *AAPS Journal*, **15(4)**, 991-1000. DOI:10.1208/s12248-013-9507-1.
130. Afrasiabi *et al.* (2013) Targeting Triple Negative Breast Cancer Cells by N<sup>3</sup>-substituted 9,10-Phenanthrenequinone thiosemicarbazones and their Metal complexes. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, **114**, 114-119. DOI:10.1016/j.saa.2013.04.122.
131. Dandawate *et al.* (2013) Novel strategies targeting cancer stem cells through phytochemicals and their analogues. *Drug Delivery and Translational Research (Theme Issue: Cancer Stem Cells)*, **3(2)**, 165-182. DOI: 10.1007/s13346-012-0079-x.
132. Li *et al.* (2013) Pancreatic cancer stem cells: Emerging target for designing novel therapy. *Cancer Letters*, **338(1)**, 94-100. DOI:10.1016/j.canlet.2012.03.018.
133. Bao *et al.* (2012) Targeting CSC-related miRNAs for cancer therapy by natural agents. *Current Drug Targets*, **13** (14), 1858-1868. CDT-EPUB-20121106-16.
134. Pradhan *et al.* (2012) From body art to anticancer activities: perspectives on medicinal properties of Henna. *Current Drug Targets*, **13** (14), 1777-1798. CDT-EPUB-20121106-10.
135. Ullah *et al.* (2012) Ascorbic acid in cancer chemoprevention: translational perspectives and efficacy. *Current Drug Targets*, **13** (14), 1757-1771. CDT-EPUB-20121106-8.
136. Xia *et al.* (2012) Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. *Current Drug Targets*, **13** (14), 1750-1756. CDT-EPUB-20121106-7.
137. Li *et al.* (2012) Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. *Epigenetics*, **7(8)**, 940-949. DOI:10.4161/epi.21236.

138. Tang *et al.* (2012) The role of microRNAs in breast cancer migration, invasion and metastasis. *International Journal of Molecular Sciences*, **13(10)**, 13414-13437. DOI:10.3390/ijms131013414.
139. Bao *et al.* (2012) Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. *PLoS ONE*, **7(12)**, e50165. DOI:10.1371/journal.pone.0050165.
140. Kong *et al.* (2012) Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. *PLoS ONE*, **7(9)**, e45045. DOI:10.1371/journal.pone.0045045.
141. Padhye *et al.* (2012) Perspectives on medicinal properties of Plumbagin and its analogs. *Medicinal Research Reviews*, **32(6)**, 1131-1158. DOI: 10.1002/med.20235.
142. Bao *et al.* (2012) Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. *Expert Opinion On Therapeutic Targets*, **16(10)**, 1041-1054.
143. Biersack *et al.* (2012) Coinage metal complexes against breast cancer. *Current Medicinal Chemistry*, **19**, 3949-3956.
144. Bao *et al.* (2012) Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. *PLoS ONE*, **7(8)**, e43726. DOI:10.1371/journal.pone.0043726.
145. Bao *et al.* (2012) The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. *Biochimica et Biophysica Acta (BBA) – Reviews on Cancer*, **1826(2)**, 272-296. DOI:10.1016/j.bbcan.2012.04.008.
146. Zubair *et al.* (2012) Apogossypolone, derivative of gossypol, mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage. *European Journal of Pharmaceutical Sciences*, **47(1)**, 280-286. DOI:10.1016/j.ejps.2012.04.014.
147. Li *et al.* (2012) Targeting bone remodeling by Isoflavone and 3,3'-Diindolylmethane in the context of Prostate Cancer Bone Metastasis. *PLoS ONE*, **7(3)**, e33011. DOI:10.1371/journal.pone.0033011.
148. Dandawate *et al.* (2012) Inclusion complex of novel curcumin analogue CDF and  $\beta$ -Cyclodextrin (1:2) and its enhanced in vivo anticancer activity against Pancreatic Cancer. *Pharmaceutical Research*, **29(7)**, 1775-1786. DOI:10.1007/s11095-012-0700-1.
149. Azam *et al.* (2012) A novel Ru(II) complex derived from hydroxydiamine as a potential antitumor agent: Synthesis and Structural Characterization. *Inorganic Chemistry Communications*, **20**, 252-258. DOI:10.1016/j.inoche.2012.03.019.
150. Bao *et al.* (2012) Curcumin analog CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. *Cancer Research*, **72(1)**, 335-345. DOI: 10.1158/0008-5472.CAN-11-2182.
151. Bao *et al.* (2012) The immunological contribution of NF- $\kappa$ B within the tumor microenvironment: A potential protective role of zinc as an anti-tumor agent. *Biochimica et Biophysica Acta (BBA) – Reviews on Cancer*, **1825(2)**, 160-172. DOI:10.1016/j.bbcan.2011.11.002.
152. Li *et al.* (2012) Targeting the Hedgehog signaling pathway for cancer therapy. *Expert Opinion On Therapeutic Targets*, **16(1)**, 49-66. DOI: 10.1517/14728222.2011.617367.
153. Salama *et al.* (2012) Lung Cancer Stem Cells: Current Progress and Future Perspectives. *J Stem Cell Res Ther*, S7:007. DOI: 10.4172/2157-7633.S7-007.
154. Ahmad *et al.* (2012) Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling. *Carcinogenesis*, **33(12)**, 2450-2456. DOI:10.1093/carcin/bgs290.
155. Ahmad *et al.* (2012) Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo leading to anticancer activity against breast cancer cells. *Molecular Cancer Therapeutics*, **11(10)**, 2193-2201. DOI:10.1158/1535-7163.MCT-12-0232-T.

156. Hassan *et al.*\* (2012) Recent updates on the role of microRNAs in prostate cancer. *J Hematol Oncol*, **5**: 9. DOI:10.1186/1756-8722-5-9. \*Equal Contributing First Author
157. Ahmad *et al.* (2012) Novel targets for detection of cancer and their modulation by chemopreventive natural compounds. *Frontiers in Bioscience (Elite Ed)*, **4**, 410-425.
158. Khan *et al.* (2012) A prooxidant mechanism for the anticancer and chemopreventive properties of plant polyphenols. *Current Drug Targets*, **13** (14), 1738-1749. CDT-EPUB-20121106-6.
159. Ahmad *et al.* (2012) Targeted regulation of PI3K/Akt/mTOR/NF- $\kappa$ B signaling by indole compounds and their derivatives: Mechanistic details and biological implications for cancer therapy. *Anti Cancer Agents in Medicinal Chemistry*, **13**(7), 1002-1013. DOI:10.2174/18715206113139990078.
160. Dandawate *et al.* (2012) Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells. *Bioorganic & Medicinal Chemistry Letters*, **22**(9), 3104-3108. DOI:10.1016/j.bmcl.2012.03.060.
161. Ahmad *et al.* (2012) Deregulation of PI3K/Akt/mTOR signaling pathway by isoflavones and its implication in cancer treatment. *Anti Cancer Agents in Medicinal Chemistry*, **13**(7), 1014-1024. DOI:10.2174/18715206113139990117.
162. Vyas *et al.* (2012) ATRA-hydrazonate derivatives and their copper complexes against hormone -dependent (MCF-7), hormone -independent (MDA-MB-231 and BT-20) breast cancer and androgen-independent (PC3) prostate cancer cell lines. *Inorganic Chemistry Communications*, **23**, 17-20. DOI:10.1016/j.inoche.2012.05.027.
163. Ahmad *et al.* (2011) Phosphoglucose Isomerase/Autocrine Motility Factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. *Cancer Research*, **71**(9), 3400-3409. DOI:10.1158/0008-5472.CAN-10-0965.
164. Ullah *et al.* (2011) Soy isoflavone genistein induces cell death in breast cancer cells through mobilization of endogenous copper ions and generation of reactive oxygen species. *Molecular Nutrition & Food Research*, **55**(4), 553-559. DOI:10.1002/mnfr.201000329.
165. Ahmad *et al.* (2011) Mechanisms and therapeutic implications of cell death induction by indole compounds. *Cancers*, **3**(3), 2955-2974. DOI:10.3390/cancers3032955.
166. Ahmad *et al.* (2011) Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF- $\kappa$ B signaling. *Frontiers in Bioscience (Elite Ed)*, **3**, 1483-1492.
167. Ahmad *et al.* (2011) Role of Nuclear Factor-kappa B signaling in anticancer properties of indole compounds. *Journal of Experimental and Clinical Medicine\**, **3**(2), 55-62. DOI:10.1016/j.jecm.2011.01.001. \*Figure selected as cover figure for the journal
168. Patitungkhua *et al.* (2011) Synthesis, Characterization and anti-tumor activity of Moxifloxacin-Copper complexes against breast cancer cell lines. *Bioorganic & Medicinal Chemistry Letters*, **21**(6), 1802-1806. DOI:10.1016/j.bmcl.2011.01.061.
169. Ahmad *et al.* (2011) 3, 3'-Diindolylmethane enhances Taxotere-induced growth inhibition of breast cancer cells through down-regulation of FoxM1. *International Journal of Cancer*, **129**(7), 1781-1791. DOI:10.1002/ijc.25839.
170. Ahmad *et al.* (2011) Role of Vacuolar ATPase in the Trafficking of Renal Type IIa Sodium-phosphate Cotransporter. *Cellular Physiology and Biochemistry*, **27**(6), 703-714. DOI:10.1159/000330079.
171. Vyas *et al.* (2011) Perspectives on Medicinal properties of Mangiferin. *Mini Reviews in Medicinal Chemistry*, **12** (5), 412-425.
172. Bao *et al.* (2011) Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. *Cancer Prevention Research*, **5**(3), 355-364. DOI: 10.1158/1940-6207.CAPR-11-0299.
173. Li *et al.* (2011) Induction of cancer cell death by isoflavone: the role of multiple signaling pathways. *Nutrients*, **3**(10), 877-896. DOI:10.3390/nu3100877.

174. Schobert *et al.* (2011) Cancer selective metallocenedicarboxylates of the fungal cytotoxin illudin M. *Journal of Medicinal Chemistry*, **54(18)**, 6177-6182. DOI: 10.1021/jm200359n.
175. Ali *et al.* (2011) Expression of MicroRNAs: Potential Molecular Link between Obesity, Diabetes and Cancer. *Obesity Reviews*, **12(12)**, 1050-1062. DOI: 10.1111/j.1467-789X.2011.00906.x.
176. Khan *et al.* (2011) Oral Administration of copper to rats leads to increased lymphocyte cellular DNA degradation by dietary polyphenols: implications for a cancer preventive mechanism. *Biometals*, **24(6)**, 1169-1178. DOI: 10.1007/s10534-011-9475-9.
177. Li *et al.* (2011) Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuate the aggressive behavior of prostate cancer cells. *Cancer Prevention Research*, **4(9)**, 1-12. DOI: 10.1158/1940-6207.CAPR-11-0077.
178. Ullah *et al.* (2011) The prooxidant action of dietary antioxidants leading to cellular DNA breakage and anticancer effects: implications for chemotherapeutic action against cancer. *Cell Biochemistry and Biophysics*, **67(2)**, 431-438. DOI:10.1007/s12013-011-9303-4.
179. Wang *et al.* (2011) Targeting Notch to Eradicate Pancreatic Cancer Stem Cells for Cancer Therapy. *Anticancer Research*, **31(4)**, 1105-1113.
180. Zoldakova *et al.* (2011) (Carboxydiamine)Pt(II) complexes of a combretastatin A-4 analogous chalcone: influence of the diamine ligand on DNA binding and anticancer effects. *Medicinal Chemistry Communications*, **2**, 493-499. DOI: 10.1039/C1MD00042J.
181. Liao *et al.* (2011) Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF- $\kappa$ B signaling pathways. *Journal of Cellular Biochemistry*, **112(4)**, 1055-1065. DOI: 10.1002/jcb.23019.
182. Bao *et al.* (2011) The complexities of obesity, diabetes, and the development and progression of pancreatic cancer. *Biochimica et Biophysica Acta (BBA) – Reviews on Cancer*, **1815(2)**, 135-146. DOI:10.1016/j.bbcan.2010.11.003.
183. Wang *et al.* (2011) Pancreatic cancer: understanding and overcoming chemoresistance. *Nature Reviews Gastroenterology and Hepatology*, **8(1)**, 27-33. DOI:10.1038/nrgastro.2010.188.
184. Dou *et al.* (2011) Tumor cell growth inhibition is correlated with levels of capsaicin present in hot peppers. *Nutrition and Cancer*, **63(2)**, 272-281. DOI:10.1080/01635581.2011.523497.
185. Kong *et al.* (2010) Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells. *PLoS One*, **5(8)**, e12445. DOI:10.1371/journal.pone.0012445.
186. Wang *et al.* (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. *Drug Resistance Updates*, **13(4-5)**, 109-118. DOI:10.1016/j.drug.2010.07.001.
187. Padhye *et al.* (2010) Fluorinated 2'-Hydroxychalcones as Garcinol Analogs with Enhanced Antioxidant and Anticancer Activities. *Bioorganic & Medicinal Chemistry Letters*, **20(19)**, 5818-5821. DOI:10.1016/j.bmcl.2010.07.128.
188. Wang *et al.* (2010) Targeting Notch signaling pathway to overcome drug-resistance for cancer therapy. *Biochimica et Biophysica Acta (BBA) – Reviews on Cancer*, **1806(2)**, 258-267. DOI:10.1016/j.bbcan.2010.06.001.
189. Wang *et al.* (2010) Emerging roles of PDGF-D signaling pathway in tumor development and progression. *Biochimica et Biophysica Acta (BBA) – Reviews on Cancer*, **1806(1)**, 122-130. DOI:10.1016/j.bbcan.2010.04.003.
190. Wang *et al.* (2010) FoxM1 is a novel target of a natural agent in pancreatic cancer. *Pharmaceutical Research*, **27(6)**, 1159-1168. DOI: 10.1007/s11095-010-0106-x.
191. Hadi *et al.* (2010) Resveratrol mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for chemoprevention of cancer. *Pharmaceutical Research*, **27(6)**, 979-988. DOI: 10.1007/s11095-010-0055-4.

192. Wang *et al.* (2010) Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. *Cancer Letters*, **292(2)**, 141-148. DOI:10.1016/j.canlet.2009.11.012.
193. Wang *et al.* (2010) Forkhead Box M1 transcription factor: A novel target for cancer therapy. *Cancer Treatment Reviews*, **36(2)**, 151-156. DOI:10.1016/j.ctrv.2009.11.006.
194. Ahmad *et al.* (2010) Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. *Current Drug Targets*, **11(6)**, 652-666.
195. Ahmad *et al.* (2010) Apoptosis-inducing effect of garcinol is mediated by NF- $\kappa$ B signaling in breast cancer cells. *Journal of Cellular Biochemistry* **109(6)**, 1134-1141. DOI: 10.1002/jcb.22492.
196. Ahmad *et al.* (2009) Aging and inflammation: Etiological culprits of cancer. *Current Aging Science*, **2(3)**, 174-186.
197. Ahmad *et al.* (2009) Inactivation of uPA and its receptor uPAR by 3, 3'-Diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. *Journal of Cellular Biochemistry*, **107 (3)**, 516-527. DOI:10.1002/jcb.22152.
198. Padhye *et al.* (2009) Emerging role of Garcinol, the antioxidant chalcone from *Garcinia indica* Choisy and its synthetic analogs. *Journal of Hematology & Oncology* **2:38**. DOI:10.1186/1756-8722-2-38.
199. **Nazeem *et al.* (2009)** Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. *Mutagenesis*, **24(5)**, 413-418. DOI:10.1093/mutage/geb023.
200. Kong *et al.* (2009) miR-200 regulates PDGF-D mediated epithelial-mesenchymal transition, adhesion and invasion of prostate cancer cells. *Stem Cells*, **27(8)**, 1712-1721. DOI:10.1002/stem.101.
201. Rahman *et al.* (2009) DIM enhances Taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. *Cancer Research*, **69 (10)**, 4468-4475. DOI:10.1158/0008-5472.CAN-08-4423.
202. Wang *et al.* (2009) TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. *Cancer Research*, **69(7)**, 2757-2765. DOI:10.1158/0008-5472.CAN-08-3060.
203. Wang *et al.* (2009) Acquisition of Epithelial-Mesenchymal Transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of Notch signaling pathway. *Cancer Research*, **69(6)**, 2400-2407. DOI:10.1158/0008-5472.CAN-08-4312.
204. Padhye *et al.* (2008) From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. *Cancer Therapy*, **6(B)**, 495-510.
205. Azmi *et al.* (2008) Chemoprevention of Pancreatic Cancer: Characterization of Par-4 and its Modulation by 3,3' Diindolylmethane (DIM). *Pharmaceutical Research*, **25(9)**, 2117-2124. DOI:10.1007/s11095-008-9581-8.
206. Dass *et al.* (2008) Evolving role of uPA/uPAR system in human cancers. *Cancer Treatment Reviews*, **34(2)**, 122-136. DOI:10.1016/j.ctrv.2007.10.005.
207. Ahmad *et al.* (2008) Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF- $\kappa$ B and Bcl-2. *Journal of Cellular Biochemistry*, **105 (6)**, 1461-1471. DOI:10.1002/jcb.21966 .
208. Khundmiri *et al.*\* (2008) Novel Regulatory Function for NHERF-1 in Npt2a Transcription. *American Journal of Physiology Renal Physiology*, **294 (4)**, F840-849. DOI:10.1152/ajprenal.00180.2007. \*Equal Contributing First Author
209. Ahmad *et al.* (2005) Prooxidant activity of resveratrol in the presence of copper ions: mutagenicity in plasmid DNA. *Toxicology Letters*, **159 (1)**, 1-12. DOI:10.1016/j.toxlet.2005.04.001.

210. Khundmiri *et al.* (2005) Parathyroid hormone regulation of Na<sup>+</sup>,K<sup>+</sup>-ATPase requires the PDZ 1 domain of Sodium Hydrogen Exchanger Regulatory Factor-1 in Opossum Kidney Cells. *Journal of the American Society of Nephrology*, **16(9)**, 2598-2607. DOI:10.1681/ASN.2004121049.
211. Asad *et al.* (2002) Bilirubin/Biliverdin-Cu(II) induced DNA breakage; reaction mechanism and biological significance. *Toxicology Letters*, **131(3)**, 181-189. DOI:[10.1016/S0378-4274\(02\)00031-0](https://doi.org/10.1016/S0378-4274(02)00031-0).
212. Hadi *et al.* (2001) Strand scission in DNA induced by 5-hydroxytryptamine (serotonin) in the presence of copper ions. *Neuroscience Letters*, **308(2)**, 83-86. DOI:10.1016/S0304-3940(01)01993-0.
213. Singh *et al.* (2001) Oxidative DNA damage by Capsaicin and Dihydrocapsaicin in the presence of Cu(II). *Cancer Letters*, **169(2)**, 139-146. DOI:10.1016/S0304-3835(01)00544-4.
214. Asad *et al.* (2001) Prooxidant and Antioxidant activities of Bilirubin and its metabolic precursor Biliverdin: A structure-activity study. *Chemico-Biological Interactions*, **137(1)**, 59-74. DOI:10.1016/S0009-2797(01)00209-5.
215. Ahmad *et al.* (2000) DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation. *Cancer Letters*, **154(1)**, 29-37. DOI:10.1016/S0304-3835(00)00351-7.
216. Hadi *et al.* (2000) A putative mechanism for anticancer and apoptosis inducing properties of plant derived polyphenolic compounds. *IUBMB Life*, **50(3)**, 167-171. DOI:10.1080/152165400300001471.
217. Asad *et al.* (2000) Inhibition of L-DOPA-Cu(II) mediated DNA cleavage by Bilirubin. *Toxicology in vitro*, **14(5)**, 401-404. DOI:10.1016/S0887-2333(00)00032-1.
218. Khan *et al.* (2000) Anti-oxidant, pro-oxidant properties of tannic acid and its binding to DNA. *Chemico-Biological Interactions*, **125(3)**, 177-189. DOI:10.1016/S0009-2797(00)00143-5.
219. Asad *et al.* (1999) Bilirubin-Cu(II) complex degrades DNA. *Biochimica et Biophysica Acta (BBA)*, **1428(2-3)**, 201-208. DOI:10.1016/S0304-4165(99)00075-6.
220. Asad *et al.* (1998) Flavonoids: Antioxidants in diet and potential anticancer agents. *Medical Science Research*, **26(11)**, 723-728.

## Book Chapters

1. Khan *et al.* Nuclear factor Kappa-B: bridging inflammation and cancer, *In: Gene Regulation and Therapeutics for Cancer*. Editors: Surinder K. Batra, Moorthy P. Ponnusamy. Chapter 2 (2021). CRC Press. DOI: 10.1201/b22128
2. Ginnebaugh *et al.* Updates on the promising anticancer activity of CDF, a synthetic curcumin analog (Expert Commentary). *In: Critical Dietary Factors in Cancer Chemoprevention*. Editors: Mohammad Fahad Ullah and Aamir Ahmad. (2015). Springer Publishers.
3. Ali and Ahmad. Modulation of key signaling pathways in cancer cells by dietary factors. *In: Critical Dietary Factors in Cancer Chemoprevention*. Editors: Mohammad Fahad Ullah and Aamir Ahmad. IN PRESS (2015). Springer Publishers.
4. Ahmad *et al.* miRNA targeted therapy in lung cancer, *In: MicroRNA Targeted Cancer Therapy*. Chapter 5, pp 99-114 (2014). Springer Publishers, NY. DOI:10.1007/978-3-319-05134-5\_5
5. Ahmad *et al.* Molecular targeted therapy for brain metastatic breast cancers: current updates. *In: miRNAs and Target Genes in Breast Cancer Metastasis*. Chapter 6, pp 65-75 (2014). Springer Publishers, NY. DOI: 10.1007/978-3-319-08162-5\_6
6. Li *et al.* miRNAs in Cancer Stem Cells, *In: MicroRNA in Regenerative Medicine*. Editor: C. Sen. Chapter 5, pp 137-161 (2014). DOI: 10.1016/B978-0-12-405544-5.00005-8
7. Sarkar *et al.* The therapeutic role of microRNAs in human gliomas, *In: MicroRNA Targeted Cancer Therapy*. Chapter 1, pp 1-27 (2014). Springer Publishers, NY. DOI:10.1007/978-3-319-05134-5\_1

8. Li *et al.* MicroRNA targeted therapy for overcoming drug resistance, reversal of EMT and elimination of cancer stem cells in prostate and pancreatic cancer, *In: MicroRNA Targeted Cancer Therapy*. Chapter 12, pp 199-214 (2014). Springer Publishers, NY. DOI:10.1007/978-3-319-05134-5\_12.
9. Bao *et al.* The Biological Significance of Zinc in Inflammation and Aging. *In: Inflammation, Advancing Age and Nutrition*. *Editors*: Irfan Rahman and Debasis Bagchi. Chapter 2, pp 15-27; 1<sup>st</sup> Edition. (2014). Academic Press, Elsevier, US. ISBN 978-0-12-397803-5.
10. Li *et al.* Targeting cancer stem cells for overcoming drug resistance and cancer progression, *In: Cancer Stem Cells*. *Editor*: Vinagolu K. Rajasekhar. Chapter 34, pp 461-471 (2014). John Wiley & Sons Ltd, Chichester, UK. DOI: 10.1002/9781118356203.ch34.
11. Li *et al.* The biological roles of microRNAs in cancer stem cells, *In: MicroRNAs: key regulators of oncogenesis*. *Editors*: Sadegh Babashah. Chapter 12, pp 295-320 (2014). Springer Publishers, NY. DOI: 10.1007/978-3-319-03725-7\_12 .
12. Li *et al.* The role of miRNAs in the development of normal pancreas and pancreatic cancer, and their roles in tumor progression, *In: MicroRNA in Development and in the Progression of Cancer*. *Editors*: Shree Ram Singh and Pranela Rameshwar. Chapter 10, pp 179-198 (2014). Springer Publishers, NY. DOI: 10.1007/978-1-4899-8065-6\_10.
13. Ahmad *et al.* Current understanding of drug resistance mechanisms and therapeutic targets in HER2 overexpressing breast cancers, *In: Breast Cancer Metastasis and Drug Resistance*. Chapter 15, pages 261-274; 1st Edition. (2013). Springer Publishers, NY. ISBN 978-1-4614-5646-9; e-ISBN 978-1-4614-5647-6; DOI:10.1007/978-1-4614-5647-6
14. Li *et al.* Epigenetic regulation of mRNAs and miRNAs by nutraceuticals, *In: Epigenetics and Cancer*. *Editor*: Fazlul H. Sarkar. Chapter 14, pp 251-272 (2013). Springer Publishers, NY. DOI:10.1007/978-94-007-6612-9\_14.
15. Ahmed *et al.* MicroRNAs in breast cancer research: progress and promise, *In: Breast Cancer Metastasis and Drug Resistance*. *Editor*: Aamir Ahmad. Chapter 22, pages 399-413; 1st Edition. (2013). Springer Publishers, NY. ISBN 978-1-4614-5646-9; e-ISBN 978-1-4614-5647-6; DOI:10.1007/978-1-4614-5647-6
16. Li *et al.* Cancer prevention by isoflavone, *In: Inflammation, oxidative stress, and cancer: Dietary approaches for cancer prevention*. *Editor*: Ah-Ng Tony Kong. Chapter 20, pages 387-400. (2013). CRC Press. ISBN 978-1-4665-0370-0; e-ISBN 978-1-4665-0371-7; DOI: 10.1201/b15323-27
17. Bao *et al.* The biology of the deadly love connection between obesity, diabetes, and breast cancer, *In: Breast Cancer Metastasis and Drug Resistance*. *Editor*: Aamir Ahmad. Chapter 7, pages 117-142; 1st Edition. (2013). Springer Publishers, NY. ISBN 978-1-4614-5646-9; e-ISBN 978-1-4614-5647-6; DOI:10.1007/978-1-4614-5647-6
18. Kong *et al.* Stem cells and cancer, *In: Cancer Targeted Drug Delivery: An elusive dream*. *Editors*: You Han Bae, Randall J. Mrsny and Kinam Park. Chapter 3, pages 413-433 (2013). Springer Publishers, NY. ISBN 978-1-4614-7875-1; e-ISBN 978-1-4614-7876-8; 10.1007/978-1-4614-7876-8\_16
19. Tang *et al.* The complexities of racial disparity in breast cancer, *In: Breast Cancer Metastasis and Drug Resistance*. *Editor*: Aamir Ahmad. Chapter 3, pages 35-46; 1st Edition. (2013). Springer Publishers, NY. ISBN 978-1-4614-5646-9; e-ISBN 978-1-4614-5647-6; DOI:10.1007/978-1-4614-5647-6
20. Ullah *et al.* Dietary phenolics as cancer chemopreventive Nutraceuticals: a promising paradigm. *In: Frontiers in Anti-Cancer Drug Discovery*. *Editors*: Atta-ur-Rahman and M. Iqbal Choudhary. Chapter 2, Volume 2, Pages 32-92 (2013). Bentham Science. SBN: 978-1-60805-808-2; ISBN: 978-1-60805-809-9; ISSN: 1879-6656; DOI: 10.2174/9781608058082113020005



21. Ali *et al.* The Role of microRNAs in Tumor Progression and Therapy, In MicroRNAs in Toxicology and Medicine. *Editor:* Saura C. Sahu. Chapter 9 (2013). John Wiley & Sons Ltd, Chichester, UK. DOI: 10.1002/9781118695999.ch9
22. Ahmad *et al.* Resistance and DNA repair mechanisms of cancer stem cells: potential molecular targets for therapy. *In: DNA Repair of Cancer Stem Cells*. *Editors:* Lesley A. Mathews, Stephanie M. Cabarcas and Elaine M. Hurt. Chapter 3; 1st Edition. (2012). Springer Publishers, NY. ISBN 978-94-007-4589-6
23. Ahmad *et al.* Role of novel nutraceuticals garcinol, plumbagin and mangiferin in the prevention and therapy of human malignancies: mechanisms of anticancer activity, *In: Nutraceuticals and Cancer*. Chapter 10, pages 179-199; 1st Edition. (2012). Springer Publishers, NY. ISBN 978-94-007-2629-1; e-ISBN 978-94-007-2630-7; DOI:10.1007/978-94-007-2630-7
24. Ahmad *et al.* Cell Cycle Regulatory Proteins in Breast Cancer: Molecular Determinants of Drug Resistance and Targets for Anticancer Therapies. *In: Breast Cancer Cells / Book 2*. *Editor:* Rebecca L. Aft. Chapter 8, pages 113-130 (2012). Publisher: InTech - Open Access Publisher. ISBN 978-953-51-0145-1
25. Bao *et al.* The Protective Role of Zinc in Cancer: A Potential Chemopreventive Agent. *In: Nutrition, Diet and Cancer*. *Editors:* S. Shankar and R. Srivastava. Chapter 12, pages 249-275 (2012). Springer Publishers, NY. ISBN 978-94-007-2923-0. DOI 10.1007/978-94-007-2923-0 12
26. Li *et al.* Augmenting the efficacy of chemo- and radio-therapy by nutraceuticals: evidence from pre-clinical and clinical trials. *In: Nutraceuticals and Cancer*. Chapter 16, pages 355-376; 1st Edition. (2012). Springer Publishers, NY. ISBN 978-94-007-2629-1; e-ISBN 978-94-007-2630-7; DOI:10.1007/978-94-007-2630-7
27. Wang *et al.* Targeting Notch Genes for Novel Therapy in Pancreatic Cancer. *In: Advances in Genetics Research*. Volume 7. *Editor:* Kevin V. Urbano. Chapter 6, pages 175-192 (2012). Nova Publishers, NY. ISBN 978-1-61470-029-6
28. Ahmad *et al.* MicroRNAs: Targets of interest in breast cancer research. *In: MicroRNA: Expression, Detection and Therapeutic Strategies*. Chapter 3, pages 59-78 (2011). Nova Publishers, NY. ISBN 978-1-61122-846-5
29. Ali *et al.* MicroRNAs in Cancer Invasion and Metastasis. *In: MicroRNAs in Cancer Translational Research*. *Editor:* William C. S. Cho. Chapter 17, pages 389-413; 1st Edition. (2011). Springer Publishers, NY. ISBN 978-94-007-0297-4; e-ISBN 978-94-007-0298-1; DOI:10.1007/978-94-007-0298-1

## Editorial Responsibilities

1. **Editor-in-chief** of Journal “**Non-coding RNA Research**” (Elsevier / KeAi Publishers)
2. Cancer Editor for journal Scientific Reports
3. Editorial Board Member for journal Cancers
4. Associate Editor for ‘Molecular and Cellular Oncology’ section of journals Frontiers in Cell and Developmental Biology and Frontiers in Oncology
5. Editorial Board Member for journal International Journal of Molecular Sciences
6. Guest Editor of Special Issue ‘lncRNAs in Cancer Metastasis and Therapy Resistance Volume II’ for journal Frontiers in Oncology
7. Guest Editor of Special Issue ‘Emerging Targets and Therapeutic Strategies in Cancer’ for journal Cells
8. Guest Editor of Special Issue ‘Insights in Molecular and Cellular Oncology: 2022’ for journal Frontiers in Oncology
9. Guest Editor of Special Issue ‘CAR T-Cell Therapy 2.0’ for journal International Journal of Molecular Sciences

10. Guest Editor of Special Issue 'Exosomes in Cancer Diagnosis and Therapy 2.0' for journal International Journal of Molecular Sciences
11. Guest Editor of Special Issue 'CAR T-Cell Therapy' for journal International Journal of Molecular Sciences
12. Guest Editor of Special Issue 'lncRNAs in Cancer Metastasis and Therapy Resistance' for journals Frontiers in Oncology & Frontiers in Cell and Developmental Biology
13. Guest Editor of Special Issue 'Cancer Drug Resistance: An Epigenetic Approach' for journal Cancers
14. Guest Editor of Special Issue 'Exosomes in Cancer Diagnosis and Therapy' for journal International Journal of Molecular Sciences
15. Editor-in-Charge for Guest Edited Collection 'Epigenetics within the tumor microenvironment' for journal Scientific Reports
16. Guest Editor of Special Issue 'CAR T-Cell Therapy' for journal International Journal of Molecular Sciences
17. Guest Editor of Special Issue 'Epigenetic Basis of Cancer Drug Resistance' for journal Cancer Drug Resistance
18. Managing Guest Editor –Thematic Issue “Cancer Epigenetics” for journal *Current Cancer Drug Targets*. Published Jan 2018
19. **Books**  
**Editor-in-Chief** of book series “**Cancer Metastasis**” (Elsevier Inc.)
  - ❖ **Editor**, “**Breast Cancer Metastasis and Drug Resistance- Challenges and Progress**”, 2<sup>nd</sup> Edition, 2019, Springer Publishers. This book is part of the series ‘*Advances in Experimental Medicine and Biology*’.
  - ❖ **Co-Editor**, “**Nutraceuticals and Natural Product Derivatives: Disease Prevention and Drug Discovery**”, 2019, Wiley Publishers.
  - ❖ **Co-Editor**, “**Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management**”, Springer Publishers (2016), part of the series ‘*Advances in Experimental Medicine and Biology*’. ISBN 978-3-319-24932-2
  - ❖ **Editor**, “**Introduction to Cancer Metastasis**”, Elsevier Inc. (Dec 2016).
  - ❖ **Co-Editor**, “**Lung Cancer and Personalized Medicine: Current Knowledge and Therapies**”, Springer Publishers (2015), part of the series ‘*Advances in Experimental Medicine and Biology*’. ISBN 978-3-319-24223-1
  - ❖ **Co-Editor**, “**Critical Dietary Factors in Cancer Chemoprevention**”, Springer Publishers (2015). ISBN 978-3-319-21460-3.
  - ❖ **Editor**, “**Breast Cancer Metastasis and Drug Resistance**”, Springer Publishers (2013). ISBN 978-1-4614-5647-6.
  - ❖ **Editor**, “**Soy: Nutrition, Consumption and Health**”, Nova Publishers (2012). ISBN 978-1-62081-847-3.
20. Adhoc Reviewer of more than 40 journals

## Personal Data

**US Citizen.** Born February 28, 1975